Can-Fite BioPharma (CANF) Reports FY22, Provides Clinical Update

Go back to Can-Fite BioPharma (CANF) Reports FY22, Provides Clinical Update

Can-Fite Reports 2022 Financial Results & Provides Clinical Update

March 30, 2023 7:15 AM EDT

PETACH TIKVA, Israel--(BUSINESS WIRE)-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the year ended December 31, 2022.

2022 & Recent Corporate and Clinical Development Highlights... More